Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

<p>Evaluation of co-inhibitory molecules by patient response. Total T cells at screening and C1D15 were identified as being CD4+ or CD8+ and patients were grouped by best clinical response as partial response (PR) or non-PR. The percentage of each T cell subset expressing (A) PD-1, (B) LAG3, (...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autor: Dwight H. Owen (15034782) (author)
Daljnji autori: Brooke Benner (15054338) (author), Lai Wei (15023852) (author), Vineeth Sukrithan (15054341) (author), Ashima Goyal (15054344) (author), Ye Zhou (15054347) (author), Carly Pilcher (15054350) (author), Sheryl-Ann Suffren (15054353) (author), Gwen Christenson (15054356) (author), Nancy Curtis (15054359) (author), Megan Jukich (15054362) (author), Emily Schwarz (15054365) (author), Himanshu Savardekar (15054368) (author), Ruthann Norman (15054371) (author), Sarah Ferguson (15054374) (author), Barbara Kleiber (15054377) (author), Robert Wesolowski (8863505) (author), William E. Carson (15054380) (author), Gregory A. Otterson (15054383) (author), Claire F. Verschraegen (15054386) (author), Manisha H. Shah (15054389) (author), Bhavana Konda (15054392) (author)
Izdano: 2025
Teme:
Cancer
Therapeutic Research and Development
Immuno-oncology
Clinical Research and Trials
Chemotherapy
Combination chemotherapy
Clinical Trial Results
Phase II clinical trials
Endocrine-Related Cancers
Immunotherapy
Checkpoint blockade
Lung Cancer
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti